<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04726332</url>
  </required_header>
  <id_info>
    <org_study_id>XL102-101</org_study_id>
    <nct_id>NCT04726332</nct_id>
  </id_info>
  <brief_title>Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors</brief_title>
  <official_title>A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL102 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exelixis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exelixis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, dose-escalation and expansion study evaluating the safety,&#xD;
      tolerability, PK, antitumor activity, and effect on biomarkers of XL102 administered orally&#xD;
      alone and in multiple combination regimens to subjects with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2021</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>single-agent and combination therapy dose-escalation followed by cohort-expansion</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-Escalation Stage: MTD/recommended dose for XL102</measure>
    <time_frame>Approximately 18 months</time_frame>
    <description>To determine the MTD and/or RD for further evaluation of XL102 when administered orally alone and in combination therapy in subjects with advanced solid tumors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort-Expansion Stage: Objective Response Rate (ORR)</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>To evaluate preliminary efficacy of XL102 when administered alone and in combination therapy by estimating the ORR as assessed by the Investigator per RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of XL102 as evaluated by Incidence and Severity of Adverse Events (AEs)</measure>
    <time_frame>Approximately 30 months</time_frame>
    <description>To evaluate the safety of XL102 when administered orally alone and in combination therapy through the evaluation of overall incidence of AEs, severity grade, relationship to study treatment, and laboratory tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of XL102 as evaluated by Study Treatment Exposure, Dose Intensity and Modifications, and Study Treatment Discontinuation due to AE</measure>
    <time_frame>Approximately 30 months</time_frame>
    <description>To evaluate the tolerability of XL102 when administered orally alone and in combination therapy through the evaluation of study treatment exposure, dose intensity, dose modifications, and study treatment discontinuation due to AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-Escalation Stage: Drug-Drug Interactions</measure>
    <time_frame>Approximately 18 months</time_frame>
    <description>To assess drug-drug interactions between XL102 and combination agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-Escalation Stage: Time to Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>Approximately 18 months</time_frame>
    <description>To evaluate the Tmax of XL102 alone and in combination therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-Escalation Stage: Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Approximately 18 months</time_frame>
    <description>To evaluate the Cmax of XL102 alone and in combination therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-Escalation Stage: Area Under the Plasma Concentration-Time Curve Over the Last 24-hour Dosing Interval (AUC 0-24)</measure>
    <time_frame>Approximately 18 months</time_frame>
    <description>To evaluate the AUC 0-24 of XL102 alone and in combination therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-Escalation Stage: Terminal Half-Life</measure>
    <time_frame>Approximately 18 months</time_frame>
    <description>To evaluate the terminal half-life of XL102 alone and in combination therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-Escalation Stage: Apparent Clearance (CL/F)</measure>
    <time_frame>Approximately 18 months</time_frame>
    <description>To evaluate the CL/F of XL102 alone and in combination therapy</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">298</enrollment>
  <condition>Neoplasm Malignant</condition>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Hormone Receptor Positive Breast Carcinoma</condition>
  <condition>Metastatic Castration-resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>XL102 Single-Agent Dose-Escalation Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects (Cohort A) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XL102 Single-Agent Expansion Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with triple-negative breast cancer (TNBC) (Cohort D), epithelial ovarian cancer (EOC) (Cohort E), hormone receptor-positive breast cancer (HR+ BC) (Cohort F), and metastatic castration-resistant prostate cancer (mCRPC) (Cohort G).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XL102 + Fulvestrant Dose-Escalation Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with HR+ BC (Cohort B) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XL102 + Abiraterone/Prednisone Dose-Escalation Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with mCRPC (Cohort C) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XL102 + Fulvestrant Expansion Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with HR+ BC (Cohort H).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XL102 + Abiraterone/Prednisone Expansion Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with mCRPC (Cohort I).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XL102</intervention_name>
    <description>oral doses of XL102</description>
    <arm_group_label>XL102 + Abiraterone/Prednisone Dose-Escalation Cohorts</arm_group_label>
    <arm_group_label>XL102 + Abiraterone/Prednisone Expansion Cohorts</arm_group_label>
    <arm_group_label>XL102 + Fulvestrant Dose-Escalation Cohorts</arm_group_label>
    <arm_group_label>XL102 + Fulvestrant Expansion Cohorts</arm_group_label>
    <arm_group_label>XL102 Single-Agent Dose-Escalation Cohorts</arm_group_label>
    <arm_group_label>XL102 Single-Agent Expansion Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>fulvestrant 500 mg administered as an intramuscular (IM) injection every 2 weeks for the first 3 doses and then every 4 weeks.</description>
    <arm_group_label>XL102 + Fulvestrant Dose-Escalation Cohorts</arm_group_label>
    <arm_group_label>XL102 + Fulvestrant Expansion Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone</intervention_name>
    <description>abiraterone 1000 mg administered orally once daily.</description>
    <arm_group_label>XL102 + Abiraterone/Prednisone Dose-Escalation Cohorts</arm_group_label>
    <arm_group_label>XL102 + Abiraterone/Prednisone Expansion Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>prednisone 5 mg administered orally twice daily.</description>
    <arm_group_label>XL102 + Abiraterone/Prednisone Dose-Escalation Cohorts</arm_group_label>
    <arm_group_label>XL102 + Abiraterone/Prednisone Expansion Cohorts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cytologically or histologically and radiologically confirmed solid tumor that is&#xD;
             inoperable, locally advanced, metastatic, or recurrent.&#xD;
&#xD;
          -  Dose-Escalation Stage Cohort A (Solid Tumors): The subject has a solid tumor that is&#xD;
             unresectable or metastatic and for which life-prolonging measures do not exist or&#xD;
             available therapies are intolerable or no longer effective.&#xD;
&#xD;
          -  Dose-Escalation Stage Cohort B and Cohort-Expansion Stage Cohorts F and H (Hormone&#xD;
             Receptor-Positive Breast Cancer): Subjects with breast cancer that is hormone&#xD;
             receptor-positive (estrogen receptor positive [ER+] and/or progesterone receptor&#xD;
             positive [PR+]) and negative for human epidermal growth factor receptor 2 (HER-2&#xD;
             negative [HER-2-]) and who have documented radiographic disease progression during or&#xD;
             following their last systemic anticancer therapy for inoperable locally advanced or&#xD;
             metastatic disease.&#xD;
&#xD;
          -  Dose-Escalation Stage Cohort C and Cohort-Expansion Stage Cohorts G and I (Metastatic&#xD;
             Castration-Resistant Prostate Cancer): Subjects with adenocarcinoma of the prostate.&#xD;
             Note: Neuroendocrine differentiation and other histological features are permitted if&#xD;
             adenocarcinoma is the primary histology.&#xD;
&#xD;
          -  Cohort-Expansion Stage Cohort D (Triple Negative Breast Cancer): Subjects with breast&#xD;
             cancer that is negative for HER-2, estrogen receptors, and progesterone receptors, and&#xD;
             who have documented radiographic disease progression during or following their last&#xD;
             systemic anticancer therapy for inoperable locally advanced or metastatic disease.&#xD;
&#xD;
          -  Cohort-Expansion Stage Cohort E (Epithelial Ovarian Cancer): Subjects with epithelial&#xD;
             ovarian cancer, including primary peritoneal cancer (PPC) and fallopian tube cancer&#xD;
             (FTC) who have platinum-resistant disease following treatment with a&#xD;
             platinum-containing chemotherapy. Ovarian borderline epithelial tumors (low malignant&#xD;
             potential) are excluded.&#xD;
&#xD;
          -  Expansion Cohorts: Subjects must have measurable disease per RECIST 1.1 as determined&#xD;
             by the Investigator.&#xD;
&#xD;
          -  Tumor tissue material (archival or fresh tumor tissue [if it can be safely obtained]).&#xD;
&#xD;
          -  Recovery to baseline or ≤ Grade 1 severity (Common Terminology Criteria for Adverse&#xD;
             Events version 5 [CTCAE v5]) from AEs.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.&#xD;
&#xD;
          -  Adequate organ and marrow function.&#xD;
&#xD;
          -  Sexually active fertile subjects and their partners must agree to use medically&#xD;
             accepted methods of contraception.&#xD;
&#xD;
          -  Female subjects of childbearing potential must not be pregnant at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of XL102 or any other selective CDK7 inhibitor.&#xD;
&#xD;
          -  Receipt of any cytotoxic chemotherapy therapy or anticancer antibody therapy within 21&#xD;
             days before first dose of study treatment.&#xD;
&#xD;
          -  Receipt of any type of small molecule kinase inhibitor within 2 weeks before first&#xD;
             dose of study treatment.&#xD;
&#xD;
          -  Receipt of any anticancer hormonal therapy within 2 weeks or within 5 half-lives of&#xD;
             the agent, whichever is shorter, before first dose of study treatment.&#xD;
&#xD;
          -  HR+BC subjects enrolled in the Combination Cohorts B and H receiving fulvestrant prior&#xD;
             to first dose of study treatment are allowed to continue with their fulvestrant&#xD;
             treatment.&#xD;
&#xD;
          -  Metastatic CRPC subjects enrolled in the Combination Cohorts C and I receiving&#xD;
             abiraterone prior to first dose of study treatment are allowed to continue with their&#xD;
             abiraterone treatment.&#xD;
&#xD;
          -  Radiation therapy within 14 days before first dose of study treatment. Subjects with&#xD;
             clinically relevant ongoing complications from prior radiation therapy are not&#xD;
             eligible.&#xD;
&#xD;
          -  Known brain metastases or cranial epidural disease unless adequately treated with&#xD;
             radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks&#xD;
             before first dose of study treatment.&#xD;
&#xD;
          -  Concomitant use of certain medications.&#xD;
&#xD;
          -  Uncontrolled, significant intercurrent or recent illness.&#xD;
&#xD;
          -  Corrected QT interval calculated by the Fridericia formula (QTcF) &gt; 480 ms per&#xD;
             electrocardiogram (ECG).&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
&#xD;
          -  Diagnosis of another malignancy within 2 years before first dose of study treatment,&#xD;
             except for superficial skin cancers, or localized, low grade tumors deemed cured and&#xD;
             not treated with systemic therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Exelixis Clinical Trials</last_name>
    <phone>1-888-EXELIXIS (888-393-5494)</phone>
    <email>druginfo@exelixis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Backup or International</last_name>
    <phone>650-837-7400</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Exelixis Clinical Site #4</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Exelixis Clinical Site #3</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Exelixis Clinical Site #2</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Exelixis Clinical Site #5</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Exelixis Clinical Site #1</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 22, 2021</study_first_submitted>
  <study_first_submitted_qc>January 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cdk7 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

